{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:06:14Z","timestamp":1756339574574,"version":"3.44.0"},"reference-count":20,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,4,22]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>In this report, two cases of patients with severe adverse events after an adjuvant treatment with capecitabine are described in detail. The first patient suffered from a severe ileocolitis, where ultimately intensive care treatment, total colectomy and ileum resection was necessary. The second patient experienced a toxic enteritis, which could be managed conservatively. Post-therapeutic DPYD genotyping was negative in the former and positive in the latter case. Patients can be categorised in normal, moderate and poor DPYD metabolisers to predict the risk of adverse events of capecitabine treatment. Guidelines in various European countries recommend pretherapeutic DPYD genotyping, whereas it is not recommended by the National Comprehensive Cancer Network in the USA. Irrespective of DPYD genotyping, strict therapeutic drug monitoring is highly recommended to reduce the incidence and severity of adverse events.<\/jats:p>","DOI":"10.1136\/bcr-2023-256980","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T13:50:46Z","timestamp":1714398646000},"page":"e256980","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Capecitabine-induced severe adverse events\u2014therapeutic drug monitoring and <i>DPYD<\/i>-gene analysis are recommended"],"prefix":"10.1136","volume":"17","author":[{"given":"Johan","family":"Perera","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Basel, Basel-Stadt, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-6709","authenticated-orcid":false,"given":"Julian","family":"S\u00fcsstrunk","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, Clarunis University Digestive Health Care Center Basel, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Thurneysen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Saint Clara Hospital Cancer Centre, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Steinemann","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, Clarunis University Digestive Health Care Center Basel, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"2025082711130110000_17.4.e256980.1","unstructured":"Dean L , Kane M . Capecitabine Therapy and DPYD Genotype, Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/"},{"key":"2025082711130110000_17.4.e256980.2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/FPC.0b013e32833c6107","article-title":"Pharm GKB summary: Fluoropyrimidine pathways","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"2025082711130110000_17.4.e256980.3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","article-title":"Dutch Pharmacogenetics working group (DPWG) guideline for the gene\u2013drug interaction of DPYD and Fluoropyrimidines","volume":"28","author":"Lunenburg","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"2025082711130110000_17.4.e256980.4","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140020-00002"},{"key":"2025082711130110000_17.4.e256980.5","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.9.33"},{"key":"2025082711130110000_17.4.e256980.6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/OP.20.00553","article-title":"All you need to know about DPYD genetic testing for patients treated with fluorouracil and Capecitabine: A practitioner-friendly guide","volume":"16","author":"Innocenti","year":"2020","journal-title":"JCO Oncology Practice"},{"key":"2025082711130110000_17.4.e256980.7","doi-asserted-by":"crossref","unstructured":"Hamzic S , Aebi S , Joerger M , et al . n.d. Fluoropyrimidine chemotherapy: recommendations for DPYD Genotyping and therapeutic drug monitoring of the Swiss group of Pharmacogenomics and Personalised therapy. Swiss Med Wkly 150:w20375. doi:10.4414\/smw.2020.20375","DOI":"10.4414\/smw.2020.20375"},{"key":"2025082711130110000_17.4.e256980.8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics implementation consortium (CPIC) guideline for Dihydropyrimidine dehydrogenase genotype and Fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2025082711130110000_17.4.e256980.9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ijc.29025","article-title":"Clinical importance of risk variants in the Dihydropyrimidine dehydrogenase gene for the prediction of early-onset Fluoropyrimidine toxicity","volume":"136","author":"Froehlich","year":"2015","journal-title":"Int J Cancer"},{"key":"2025082711130110000_17.4.e256980.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.4182"},{"key":"2025082711130110000_17.4.e256980.11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/1120009X.2021.2025316","article-title":"Capecitabine-associated Enterocolitis: narrative literature review of a rare adverse event and a case presentation","volume":"35","author":"Trontzas","year":"2023","journal-title":"J Chemother"},{"key":"2025082711130110000_17.4.e256980.12","first-page":"e189","article-title":"Cost-effectiveness of DPYD Genotyping prior to Fluoropyrimidine-based adjuvant chemotherapy for colon cancer","volume":"21","author":"Brooks","year":"2022","journal-title":"Clin Colorectal Cancer"},{"key":"2025082711130110000_17.4.e256980.13","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2147\/PGPM.S337147","article-title":"Ethnic diversity of dpd activity and the dpyd gene: review of the literature","volume":"Volume 14","author":"White","year":"2021","journal-title":"PGPM"},{"key":"2025082711130110000_17.4.e256980.14","unstructured":"Tr\u00fcmper L , Einsele H , de Wit M , et al . Berlin; in Kooperation mit Positionspapier Dihydropyrimidin-Dehydrogenase (DPD)-Testung vor Einsatz von 5-Fluorouracil, Capecitabin und Tegafur, June 2020. Available: www.dgho.de"},{"key":"2025082711130110000_17.4.e256980.15","unstructured":"Punt C . Samenstelling DCCG Werkgroep Medische Oncologie."},{"key":"2025082711130110000_17.4.e256980.16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01609","article-title":"DPD testing before treatment with Fluoropyrimidines in the Amsterdam Umcs: an evaluation of current Pharmacogenetic practice","volume":"10","author":"Martens","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025082711130110000_17.4.e256980.17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon cancer, version 2.2021","volume":"19","author":"Benson","year":"2021","journal-title":"JNCCN Journal of the National Comprehensive Cancer Network"},{"key":"2025082711130110000_17.4.e256980.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30686-7"},{"key":"2025082711130110000_17.4.e256980.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1325"},{"key":"2025082711130110000_17.4.e256980.20","unstructured":"Stanford University and St . Jude Children\u2019s Research Hospital (11\/2018) CPIC\u00ae Guideline for Fluoropyrimidines and DPYD, Update from November 2018, Available: https:\/\/cpicpgx.org\/guidelines\/guideline-for-fluoropyrimidines-and-dpyd [Accessed 17 Nov 2023]."}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-256980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:13:10Z","timestamp":1756318390000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-256980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,29]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/bcr-2023-256980"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-256980","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}